Scientists test 'Supercharged' immune cells to hunt down lingering cancer
NCT ID NCT06358430
Summary
This early-stage study is testing a new combination treatment for people with colorectal cancer who have had surgery but still have tiny amounts of cancer left in their blood. Researchers are giving patients specially engineered immune cells from donated cord blood, along with an existing cancer drug called cetuximab, to see if this approach is safe and can clear these remaining cancer cells. The main goals are to find the safest dose and see if the treatment can make the cancer undetectable in the blood.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MINIMAL RESIDUAL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.